Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rodin Therapeutics Inc.

Latest From Takeda Pharmaceutical Co. Ltd.

More Than CAR-T: Hematologic Oncology Pipeline Offers Rich Menu Of Possible Approvals

Sponsors of established products like Amgen's Kyprolis and Blincyto and Bristol's Sprycel work to bulk up labeling with new indications while FDA reviews at least six novel agents for blood cancers.

Approvals Cancer

Ireland At Impasse As 'Crunch Meeting' Fails To Unblock New Drug Logjam

Nine new therapies are stuck in the system in Ireland even though they have been approved for use and the pharmaceutical industry is not convinced by government claims that there is no more cash to fund them.

Cost Effectiveness Health Technology Assessment

Provenge To Drive Sanpower Growth And Wider China Cell Therapy Market?

China will provide a rising market potential for Sanpower’s newly acquired Dendreon and its Provenge product for prostate cancer, as part of the Chinese firm’s broader strategy, and the deal could also have an impact on the regulatory climate for cellular immunotherapies in China.

China Commercial

Interview: Setting The Course For Takeda’s R&D Future (Part 2)

Dr. Andrew Plump joined Takeda from Sanofi in 2015 as the Japanese company’s chief medical and scientific officer. In his current position, based in the US, he leads the global R&D organization, which has seen much fundamental change over the past 12 months.

Commercial Strategy
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Rodin Therapeutics Inc.
  • Senior Management
  • Adam J Rosenberg, Pres. & CEO
    Martin Jefson, PhD, CSO
    Magnus Ivarsson, PhD, VP, Head, Discovery
  • Contact Info
  • Rodin Therapeutics Inc.
    Phone: (617) 588-2600
    400 Technology Sq.
    Cambridge, MA 02139